O’Neill CJ, Deavers MT, Malpica A et al (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol 29:1034–1041...
Low-grade serous carcinoma of the ovary or peritoneum.Low-grade serous carcinoma of the ovary or peritoneum.doi:10.1093/annonc/mdw085chemotherapyhormonaltherapylow-gradeserouscarcinomaovariancancertargetedagentsOver the past decade, the strategy for clinical trial design in making progress against epithelial...
Low-grade serous carcinoma of the ovary/peritoneum is a rare epithelial cancer subtype characterized by younger age at diagnosis, relative chemoresistance, and prolonged overall survival compared with high-grade serous carcinoma. In addition, alterations in the mitogen activated protein kinase pathway are...
high grade serous ovarian carcinoma was significantly different from that of negative expression(P0.05).Conclusion The high expression of FOXQ1 in serous ovarian cancer is closely related to the survival rate of high grade serous carcinoma,but not to the low grade serous carcinoma.It can be used...
LGSOC, low-grade serous ovarian cancer; HGSOC, high-grade serous ovarian cancer; STIC, serous tubal intraepithelial carcinoma. adapted from [3], [4], [6], [7], [18] Recently, the grading system has changed from a three level of nuclear differentiation into low-grade cancers (mild or ...
A serous borderline tumor was present adjacent to the invasive carcinoma, and no benign mesonephric precursors were identified. Numerous invasive peritoneal metastases were present, including multiple metastases with both low-grade serous and mesonephric-like elements. Consistent with recent reports, foci...
Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian malignancies is not developing as we
Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian malignancies is not developing as we
Ovarian low-grade serous carcinomas are thought to evolve in a stepwise fashion from ovarian epithelial inclusions, cystadenomas, and borderline tumors. The current study was designed to gain insight into the origins of low-grade serous carcinomas (tubal
Updated findings from RAMP 201 show that avutometinib/defactinib is generally well tolerated among those with low-grade serous ovarian cancer.